Journal of Neuroimmune Pharmacology

, Volume 10, Issue 2, pp 233–244 | Cite as

Changes in the endocannabinoid signaling system in CNS structures of TDP-43 transgenic mice: relevance for a neuroprotective therapy in TDP-43-related disorders

  • Francisco Espejo-Porras
  • Fabiana Piscitelli
  • Roberta Verde
  • José A. Ramos
  • Vincenzo Di Marzo
  • Eva de Lago
  • Javier Fernández-Ruiz
INVITED REVIEW

Abstract

Because of their neuroprotective properties, cannabinoids are being investigated in neurodegenerative disorders, mainly in preclinical studies. These disorders also include amyotrophic lateral sclerosis (ALS), a degenerative disease produced by the damage of the upper and lower motor neurons leading to muscle denervation, atrophy and paralysis. The studies with cannabinoids in ALS have been conducted exclusively in a transgenic mouse model bearing mutated forms of human superoxide dismutase-1, the first gene that was identified in relation with ALS. The present study represents the first attempt to investigate the endocannabinoid system in an alternative model, the transgenic mouse model of TAR-DNA binding protein-43 (TDP-43), a protein related to ALS and also to frontotemporal dementia. We used these mice for behavioral and histological characterization at an early symptomatic phase (70–80 days of age) and at a post-symptomatic stage (100–110 days of age). TDP-43 transgenic mice exhibited a worsened rotarod performance at both disease stages. This was accompanied by a loss of motor neurons in the spinal cord (measured by Nissl staining) and by reactive microgliosis (measured by Iba-1 immunostaining) at the post-symptomatic stage. We also detected elevated levels of the CB2 receptor (measured by qRT-PCR and western blotting) in the spinal cord of these animals. Double-staining studies confirmed that this up-regulation occurs in microglial cells in the post-symptomatic stage. Some trends towards an increase were noted also for the levels of endocannabinoids, which in part correlate with a small reduction of FAAH. Some of these parameters were also analyzed in the cerebral cortex of TDP-43 transgenic mice, but we did not observe any significant change, in agreement with the absence of anomalies in cognitive tests. In conclusion, our data support the idea that the endocannabinoid signaling system, in particular the CB2 receptor, may serve for the development of a neuroprotective therapy in TDP-43-related disorders. We are presently engaged in pharmacological experiments to investigate this possibility.

Keywords

Cannabinoids CB1 and CB2 receptors Endocannabinoid enzymes Amyotrophic lateral sclerosis TDP-43 transgenic mice Spinal cord 

Supplementary material

11481_2015_9602_MOESM1_ESM.pptx (3.9 mb)
Figure S1Representative blots for CB2 receptors and FAAH, always corresponding to tissues from females. Bottom panels are the total protein bands transferred to a PVCF membrane that were used as loading controls. (PPTX 3947 kb)
11481_2015_9602_MOESM2_ESM.pptx (74 kb)
Figure S2Behavioral recording in the Water Morris test of TDP-43 transgenic and wild-type male mice at the postsymptomatic (100-110 days after birth) stage. Values are means ± SEM for 6-8 animals per group. Data were assessed by the unpaired Student’s t-test. (PPTX 73 kb)
11481_2015_9602_MOESM3_ESM.pptx (241 kb)
Figure S3Immunofluorescence for CB2 receptors (magnification was 40x) showing a complete loss of immunostaining in the spinal cord of CB2 receptor-knockout mice when compared with the signal found in wild-type mice and, in particular, TDP-43 transgenic mice at the postsymptomatic (100-110 days after birth) stage. Immunostainings were repeated in at least 3 animals per group. (PPTX 241 kb)

References

  1. Al-Chalabi A, Hardiman O (2013) The epidemiology of ALS: a conspiracy of genes, environment and time. Nat Rev Neurol 9:617–628PubMedCrossRefGoogle Scholar
  2. Alvarez FJ, Lafuente H, Rey-Santano MC et al (2008) Neuroprotective effects of the nonpsychoactive cannabinoid cannabidiol in hypoxic-ischemic newborn piglets. Pediatr Res 64:653–658PubMedCrossRefGoogle Scholar
  3. Atwood BK, Mackie K (2010) CB2: a cannabinoid receptor with an identity crisis. Br J Pharmacol 160:467–479PubMedCentralPubMedCrossRefGoogle Scholar
  4. Bilsland LG, Dick JR, Pryce G et al (2006) Increasing cannabinoid levels by pharmacological and genetic manipulation delay disease progression in SOD1 mice. FASEB J 20:1003–1005PubMedCrossRefGoogle Scholar
  5. Bisogno T, Sepe N, Melck D et al (1997) Biosynthesis, release and degradation of the novel endogenous cannabimimetic metabolite 2-arachidonoylglycerol in mouse neuroblastoma cells. Biochem J 322:671–677PubMedCentralPubMedGoogle Scholar
  6. Buratti E, Baralle FE (2010) The multiple roles of TDP-43 in pre-mRNA processing and gene expression regulation. RNA Biol 7:420–429PubMedCrossRefGoogle Scholar
  7. Cruts M, Gijselinck I, Van Langenhove T, van der Zee J, Van Broeckhoven C (2013) Current insights into the C9orf72 repeat expansion diseases of the FTLD/ALS spectrum. Trends Neurosci 36:450–459PubMedCrossRefGoogle Scholar
  8. de Lago E, Moreno-Martet M, Espejo-Porras F, Fernández-Ruiz J (2015) Endocannabinoids and amyotrophic lateral sclerosis. In: Fattore L (ed) Cannabinoids in neurologic and mental disease. Elsevier, The Netherlands, pp 99–124CrossRefGoogle Scholar
  9. Devane WA, Hanus L, Breuer A et al (1992) Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258:1946–1949PubMedCrossRefGoogle Scholar
  10. Esmaeili MA, Panahi M, Yadav S, Hennings L, Kiaei M (2013) Premature death of TDP-43 (A315T) transgenic mice due to gastrointestinal complications prior to development of full neurological symptoms of amyotrophic lateral sclerosis. Int J Exp Pathol 94:56–64PubMedCentralPubMedCrossRefGoogle Scholar
  11. Fernández-Ruiz J, Romero J, Velasco G et al (2007) Cannabinoid CB2 receptor: a new target for controlling neural cell survival? Trends Pharmacol Sci 28:39–45PubMedCrossRefGoogle Scholar
  12. Fernández-Ruiz J, García C, Sagredo O, Gómez-Ruiz M, de Lago E (2010) The endocannabinoid system as a target for the treatment of neuronal damage. Expert Opin Ther Targets 14:387–404PubMedCrossRefGoogle Scholar
  13. Ferraiuolo L, Kirby J, Grierson AJ, Sendtner M, Shaw PJ (2011) Molecular pathways of motor neuron injury in amyotrophic lateral sclerosis. Nat Rev Neurol 7:616–630PubMedCrossRefGoogle Scholar
  14. Foran E, Trotti D (2009) Glutamate transporters and the excitotoxic path to motor neuron degeneration in amyotrophic lateral sclerosis. Antioxid Redox Signal 11:1587–1602PubMedCentralPubMedCrossRefGoogle Scholar
  15. Guo Y, Wang Q, Zhang K, An T, Shi P, Li Z, Duan W, Li C (2012) HO-1 induction in motor cortex and intestinal dysfunction in TDP-43 A315T transgenic mice. Brain Res 1460:88–95PubMedCrossRefGoogle Scholar
  16. Gürtler A, Kunz N, Gomolka M et al (2013) Stain-Free technology as a normalization tool in Western blot analysis. Anal Biochem 433:105–111PubMedCrossRefGoogle Scholar
  17. Habib AA, Mitsumoto H (2011) Emerging drugs for amyotrophic lateral sclerosis. Expert Opin Emerg Drugs 16:537–558PubMedCrossRefGoogle Scholar
  18. Hardiman O, van den Berg LH, Kiernan MC (2011) Clinical diagnosis and management of amyotrophic lateral sclerosis. Nat Rev Neurol 7:639–649PubMedCrossRefGoogle Scholar
  19. Janssens J, Van Broeckhoven C (2013) Pathological mechanisms underlying TDP-43 driven neurodegeneration in FTLD-ALS spectrum disorders. Hum Mol Genet 22:R77–R87PubMedCentralPubMedCrossRefGoogle Scholar
  20. Kim K, Moore DH, Makriyannis A, Abood ME (2006) AM1241, a cannabinoid CB2 receptor selective compound, delays disease progression in a mouse model of amyotrophic lateral sclerosis. Eur J Pharmacol 542:100–105PubMedCrossRefGoogle Scholar
  21. Lagier-Tourenne C, Polymenidou M, Cleveland DW (2010) TDP-43 and FUS/TLS: emerging roles in RNA processing and neurodegeneration. Hum Mol Genet 19:R46–R64PubMedCentralPubMedCrossRefGoogle Scholar
  22. Marsicano G, Wotjak CT, Azad SC et al (2002) The endogenous cannabinoid system controls extinction of aversive memories. Nature 418:530–534PubMedCrossRefGoogle Scholar
  23. Moreno-Martet M, Espejo-Porras F, Fernández-Ruiz J, de Lago E (2014) Changes in endocannabinoid receptors and enzymes in the spinal cord of SOD1(G93A) transgenic mice and evaluation of a Sativex®-like combination of phytocannabinoids: interest for future therapies in amyotrophic lateral sclerosis. CNS Neurosci Ther 20:809–815PubMedCrossRefGoogle Scholar
  24. Patil SS, Sunyer B, Höger H, Lubec G (2009) Evaluation of spatial memory of C57BL/6 J and CD1 mice in the Barnes maze, the Multiple T-maze and in the Morris water maze. Behav Brain Res 198:58–68PubMedCrossRefGoogle Scholar
  25. Raman C, McAllister SD, Rizvi G et al (2004) Amyotrophic lateral sclerosis: delayed disease progression in mice by treatment with a cannabinoid. Amyotroph Lateral Scler Other Motor Neuron Disord 5:33–39PubMedCrossRefGoogle Scholar
  26. Renton AE, Chiò A, Traynor BJ (2014) State of play in amyotrophic lateral sclerosis genetics. Nat Neurosci 17:17–23PubMedCrossRefGoogle Scholar
  27. Ripps ME, Huntley GW, Hof PR, Morrison JH, Gordon JW (1995) Transgenic mice expressing an altered murine superoxide dismutase gene provide an animal model of amyotrophic lateral sclerosis. Proc Natl Acad Sci U S A 92:689–693PubMedCentralPubMedCrossRefGoogle Scholar
  28. Robberecht W, Philips T (2013) The changing scene of amyotrophic lateral sclerosis. Nat Rev Neurosci 14:248–264PubMedCrossRefGoogle Scholar
  29. Rosen DR, Siddique T, Patterson D et al (1993) Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 362:59–62PubMedCrossRefGoogle Scholar
  30. Shoemaker JL, Seely KA, Reed RL et al (2007) The CB2 cannabinoid agonist AM-1241 prolongs survival in a transgenic mouse model of amyotrophic lateral sclerosis when initiated at symptom onset. J Neurochem 101:87–98PubMedCentralPubMedCrossRefGoogle Scholar
  31. Tsao W, Jeong YH, Lin S, Ling J, Price DL, Chiang PM, Wong PC (2012) Rodent models of TDP-43: recent advances. Brain Res 1462:26–39PubMedCentralPubMedCrossRefGoogle Scholar
  32. Vázquez C, García MC, Tolón RM et al (2014) New mouse model for the study of CB2 cannabinoid receptors. The 24th Annual Symposium on the Cannabinoids. International Cannabinoid Research Society, Research Triangle Park, NC, USA, page 260Google Scholar
  33. Weber M, Goldman B, Truniger S (2010) Tetrahydrocannabinol (THC) for cramps in amyotrophic lateral sclerosis: a randomised, double-blind crossover trial. J Neurol Neurosurg Psychiatry 81:1135–1140PubMedCrossRefGoogle Scholar
  34. Wegorzewska I, Bell S, Cairns NJ, Miller TM, Baloh RH (2009) TDP-43 mutant transgenic mice develop features of ALS and frontotemporal lobar degeneration. Proc Natl Acad Sci U S A 106:18809–18814PubMedCentralPubMedCrossRefGoogle Scholar
  35. Weydt P, Hong S, Witting A et al (2005) Cannabinol delays symptom onset in SOD1 (G93A) transgenic mice without affecting survival. Amyotroph Lateral Scler Other Motor Neuron Disord 6:182–184PubMedCrossRefGoogle Scholar
  36. Witting A, Weydt P, Hong S et al (2004) Endocannabinoids accumulate in spinal cord of SOD1 G93A transgenic mice. J Neurochem 89:1555–1557PubMedCrossRefGoogle Scholar
  37. Yiangou Y, Facer P, Durrenberger P et al (2006) COX-2, CB2 and P2X7-immunoreactivities are increased in activated microglial cells/macrophages of multiple sclerosis and amyotrophic lateral sclerosis spinal cord. BMC Neurol 6:12PubMedCentralPubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2015

Authors and Affiliations

  • Francisco Espejo-Porras
    • 1
    • 2
    • 3
  • Fabiana Piscitelli
    • 4
  • Roberta Verde
    • 4
  • José A. Ramos
    • 1
    • 2
    • 3
  • Vincenzo Di Marzo
    • 4
  • Eva de Lago
    • 1
    • 2
    • 3
  • Javier Fernández-Ruiz
    • 1
    • 2
    • 3
  1. 1.Instituto Universitario de Investigación en Neuroquímica, Departamento de Bioquímica y Biología Molecular III, Facultad de MedicinaUniversidad ComplutenseMadridSpain
  2. 2.Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED)MadridSpain
  3. 3.Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS)MadridSpain
  4. 4.Endocannabinoid Research Group, Institute of Biomolecular Chemistry, Consiglio Nazionale delle RicerchePozzuoliItaly

Personalised recommendations